Dashboard
1
With a growth in Net Profit of 313.63%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 392.42 MM
- INTEREST COVERAGE RATIO(Q) Highest at 382.56
- ROCE(HY) Highest at 4.25%
2
With ROE of 6.85%, it has a attractive valuation with a 3.10 Price to Book Value
3
High Institutional Holdings at 100%
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
USD 7,405 Million (Small Cap)
45.00
NA
0.00%
1.33
8.35%
4.07
Revenue and Profits:
Net Sales:
3,334 Million
(Quarterly Results - Sep 2025)
Net Profit:
37 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.39%
0%
14.39%
6 Months
62.04%
0%
62.04%
1 Year
107.52%
0%
107.52%
2 Years
332.4%
0%
332.4%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
BrightSpring Health Services, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.62%
EBIT Growth (5y)
15.27%
EBIT to Interest (avg)
1.26
Debt to EBITDA (avg)
4.73
Net Debt to Equity (avg)
1.50
Sales to Capital Employed (avg)
2.40
Tax Ratio
20.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
9,390.06%
ROE (avg)
868.50%
Valuation key factors
Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
3.10
EV to EBIT
23.12
EV to EBITDA
14.87
EV to Capital Employed
1.86
EV to Sales
0.66
PEG Ratio
0.11
Dividend Yield
NA
ROCE (Latest)
8.05%
ROE (Latest)
6.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
No Trend
Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 47 Schemes (43.03%)
Foreign Institutions
Held by 82 Foreign Institutions (8.14%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
3,334.10
3,147.70
5.92%
Operating Profit (PBDIT) excl Other Income
146.30
123.00
18.94%
Interest
38.20
38.80
-1.55%
Exceptional Items
-17.70
-32.60
45.71%
Consolidate Net Profit
37.50
8.50
341.18%
Operating Profit Margin (Excl OI)
31.60%
25.80%
0.58%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 5.92% vs 9.37% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 341.18% vs -7.61% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
11,266.50
8,826.20
27.65%
Operating Profit (PBDIT) excl Other Income
509.20
392.10
29.86%
Interest
228.40
324.60
-29.64%
Exceptional Items
-111.10
-42.60
-160.80%
Consolidate Net Profit
-20.50
-156.80
86.93%
Operating Profit Margin (Excl OI)
27.10%
21.50%
0.56%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 27.65% vs 14.32% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 86.93% vs -189.30% in Dec 2023
About BrightSpring Health Services, Inc. 
BrightSpring Health Services, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






